内容紹介
Summary
Background: Neoadjuvant chemotherapy is designed to prevent disease recurrence, particularly distant recurrence, and to improve overall patient survival. We present 2 cases where pathological complete response(pCR)was obtained after administering XELOXIRI as neoadjuvant chemotherapy for locally advanced rectal cancer. Case 1: The patient was a 63-year-old man diagnosed with rectal cancer(Ra, cT4aN1M0, cStage Ⅲa)and treated with 6 courses of XELOXIRI as neoadjuvant chemotherapy. After systemic chemotherapy, he underwent laparoscopy-assisted low anterior resection and showed a pCR. Case 2: The patient was a 56-year-old man diagnosed with rectal cancer(Rb, cT3N3M0, cStage Ⅲb)and treated with 6 couses of XELOXIRI as neoadjuvant chemotherapy. After systemic chemotherapy, he underwent low anterior resection and showed a pCR. Conclusion: We present 2 cases treated with XELOXIRI as neoadjuvant chemotherapy for locally advanced rectal cancer where pCR was achieved.
要旨
局所進行直腸癌に対する術前化学療法(neoadjuvant chemotherapy: NAC)は,遠隔転移の制御および生存率の向上を期待して施行される。症例1は63歳,男性。直腸癌(Ra,cT4aN1M0,cStage Ⅲa)に対してNACとしてXELOXIRI療法を6コース施行後,ycT2N0M0,ycStageⅠの診断で腹腔鏡下低位前方切除術(D3郭清)を施行した。病理組織学的診断はpathological complete response(pCR),組織学的効果判定はGrade 3であった。症例2は56歳,男性。直腸癌(Rb,cT3N3M0,cStage Ⅲc)に対してNACとしてXELOXIRI療法を6コース施行後,ycT3N0M0,ycStageⅡの診断で腹腔鏡下低位前方切除術(D3郭清,右側方リンパ節郭清)を施行した。病理組織学的診断はpCR,組織学的効果判定はGrade 3であった。ともに無再発で外来経過観察中である。今回われわれは,術前XELOXIRI療法にてpCRを得た局所進行直腸癌の2例を経験したので報告する。
目次
Background: Neoadjuvant chemotherapy is designed to prevent disease recurrence, particularly distant recurrence, and to improve overall patient survival. We present 2 cases where pathological complete response(pCR)was obtained after administering XELOXIRI as neoadjuvant chemotherapy for locally advanced rectal cancer. Case 1: The patient was a 63-year-old man diagnosed with rectal cancer(Ra, cT4aN1M0, cStage Ⅲa)and treated with 6 courses of XELOXIRI as neoadjuvant chemotherapy. After systemic chemotherapy, he underwent laparoscopy-assisted low anterior resection and showed a pCR. Case 2: The patient was a 56-year-old man diagnosed with rectal cancer(Rb, cT3N3M0, cStage Ⅲb)and treated with 6 couses of XELOXIRI as neoadjuvant chemotherapy. After systemic chemotherapy, he underwent low anterior resection and showed a pCR. Conclusion: We present 2 cases treated with XELOXIRI as neoadjuvant chemotherapy for locally advanced rectal cancer where pCR was achieved.
要旨
局所進行直腸癌に対する術前化学療法(neoadjuvant chemotherapy: NAC)は,遠隔転移の制御および生存率の向上を期待して施行される。症例1は63歳,男性。直腸癌(Ra,cT4aN1M0,cStage Ⅲa)に対してNACとしてXELOXIRI療法を6コース施行後,ycT2N0M0,ycStageⅠの診断で腹腔鏡下低位前方切除術(D3郭清)を施行した。病理組織学的診断はpathological complete response(pCR),組織学的効果判定はGrade 3であった。症例2は56歳,男性。直腸癌(Rb,cT3N3M0,cStage Ⅲc)に対してNACとしてXELOXIRI療法を6コース施行後,ycT3N0M0,ycStageⅡの診断で腹腔鏡下低位前方切除術(D3郭清,右側方リンパ節郭清)を施行した。病理組織学的診断はpCR,組織学的効果判定はGrade 3であった。ともに無再発で外来経過観察中である。今回われわれは,術前XELOXIRI療法にてpCRを得た局所進行直腸癌の2例を経験したので報告する。